Innovent Biologics has unveiled its financial results for the mid-year period of 2025, boasting a remarkable 74.3% year-on-year surge in revenue, amounting to RMB 730 million. This significant growth is primarily attributed to the robust performance of its flagship product, Ocalivumab. As the company commemorates its 10th anniversary, it is entering an accelerated phase of its 2.0 development strategy. Notably, Ocalivumab has recently secured approval for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and has been featured as a Class I recommendation in the "Chinese Society of Clinical Oncology 2025 Lymphoma Diagnosis and Treatment Guidelines," underscoring its proven efficacy and safety. Moreover, Innovent Biologics has witnessed an 86.7% year-on-year reduction in its first-half loss, coupled with robust cash flow, positioning the company to expedite its product pipeline advancements and global expansion efforts.